

Investor Factsheet Q3 2022

Captor Therapeutics is a biopharmaceutical Company focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.

Captor Therapeutics is a Polish-Swiss Company.

Our competitive advantages

- ✓ Differentiated own portfolio of projects
- ✓ World leading E3 ligase discovery unit
- ✓ TPD platform comprising molecular glues, bifunctional degraders and E3 ligases

Targeted Protein Degradation (TPD) offers advantages over classical small molecules by: 1. removing all pathological functions; 2. potentially overcoming cancer resistance; 3. prolonged efficacy due to uncoupling pharmacokinetics from pharmacodynamics.

New significant drug discovery collaboration signed with Ono Pharmaceutical



Up to EUR 197 million (over US\$200 million) in milestone payments (including an up front payment)



Royalties on global sales

Our current projects

Target	Indications	Modality	Discovery	Preclinical*	IND Filing	FIH
GSPT1, SALL4	Hepatocellular carcinoma	MG				2023 / 2024
CT-02	Autoimmunity, Neuroinflammation, Cancer, Metabolic diseases	MG				
MCL-1	Liquid & solid tumours	BID				
CT-05	Autoimmunity Solid tumours & other	BID				
Discovery projects	Autoimmunity, Cancer	BID MG				
Partnered Projects				Partner		
Gastrointestinal diseases, e.g. IBD				Sosei Heptares		
Neurodegenerative diseases				Ono Pharmaceutical		
JUST ANNOUNCED						

*Preclinical stage include IND-enabling studies, First in Human; at least 2 projects expected to enter Phase 1 by 2023, **BID** - Bi-functional Degradere; **MG** - Molecular Glue

Key R&D Announcements

CT-01:

- Captor has nominated the clinical candidate CPT-6281. For this compound, high levels of tumour shrinkage in animal models were observed at all reported doses.
- The Company has generated *in vivo* pharmacology data, *in vivo* and *in vitro* pharmacokinetics in animal species that will be used for safety testing, and has identified service providers and designed studies in the area of toxicology.
- The Company is working with leading clinicians to assemble a clinical team with expertise both in liver cancer and early-stage clinical trials. We expect the project to enter clinical phase in 2023.

CT-03:

- The lead compounds have shown the desired pharmacological properties *in vitro* and *in vivo*

- The Company has begun the process of large-scale synthesis, which is being conducted by an experienced subcontractor. These are the first studies included in a package of so-called CTA/IND-enabling studies, which will enable the start of clinical trials.

Meet our new partner – Ono Pharmaceutical

A global pharmaceutical leader, the oldest pharmaceutical Company in Japan, with around 4.000 employees.

- In 2014, ONO has launched the world's first anti-PD-1 antibody: OPDIVO which had sales of USD 8.5 billion in 2021 through Ono and its partners.
- The Company has conducted 82 clinical trials (FY2021); launched & approved 31 products (FY2017 to FY2021),
- The up to 28% operating margin supports significant R&D Investments.

Employees (data as of 30.09.2022)


Number of employees	106
Number of research staff	93



49.46%


Research staff with PhD

Consolidated statement of financial position (PLN, M)



Available funding secured

(PLN M; as of 30.09.2022)



PLN 92 M


Cash, short-term bonds

PLN 88 M

Agreements with NCBR

Total PLN 180 M

Shareholding Structure – 30.09.2022



Share capital	Shareholder
24,11%	Michał Walczak
14,23%	Paweł Holstinghausen Holsten
8,18%	Sylvain Cottens
7,27%	Funds Managed by Nationale-Nederlanden - Powszechna Towarzystwo Emerytalne S.A.
46,21%	Others

Stock exchange info

Company listed on Warsaw Stock Exchange (GPW): CAPTORTX



Market capitalization (November 2022)

PLN 783 M

IPO value

~ PLN 150 M

IPO date

19 Apr 2021

This document has been prepared by Captor Therapeutics S.A. (the "Company") for information purposes only (the "Document"). The Document does not contain all the information that may be required to evaluate the Company (or its shares). The Document does not contain a complete and exhaustive analysis or description of situation of the Company. Any person who intends to make an investment decision relating to the Company should take into account mainly official announcements of the Company (i.e. current/periodic reports) published in accordance with the law. The document also contains certain forward-looking statements. Because of their nature, the Company makes no representation (promise, guarantee) that any of such statements will be realized or prove correct. The Company's actual future results and operations may differ materially from the forward-looking statements contained in the Document. The Document was prepared as of a specific date and the information contained therein may become outdated.

The Document does not constitute or form part of, and should not be construed as, any offer to sell or issue, or any solicitation of any offer to purchase, subscribe for or acquire, any securities of the Company or any solicitation of any investment activity in any jurisdiction in which such offer, solicitation, invitation or sale would be unlawful. No part of this Document, nor the fact of its distribution, should form the basis of, or be relied upon in connection with, any contract, commitment or investment decision. The Document is not intended for publication, release or distribution in, or should not be distributed or transmitted to, any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.